Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
BBC3
REST API REST API
Homo sapiens
BBC3 is differentially expressed in 195 experiments: 85 organism parts: prostate, lung, ... (83 more);, 118 disease states: normal, acute promyelocytic leukemia, ... (116 more);, 53 cell types 125 cell lines 24 compound treatments and 59 other conditions.
Synonyms PUMA, JFY1
Orthologs BBC3 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, protein binding, apoptosis, activation of caspase activity, determination of adult lifespan, mitochondrial outer membrane, induction of apoptosis, negative regulation of growth, DNA damage response, signal transduction by p53 class mediator resulting in induction of apoptosis, release of sequestered calcium ion into cytosol, mitochondrion, positive regulation of thymocyte apoptosis, activation of pro-apoptotic gene products, protein insertion into mitochondrial membrane involved in induction of apoptosis, cellular response to hypoxia, induction of apoptosis by intracellular signals, release of cytochrome c from mitochondria, positive regulation of release of cytochrome c from mitochondria, reduction of endoplasmic reticulum calcium ion concentration, positive regulation of protein homooligomerization
UniProt Accession Q96PG8, B4DQK3, Q9BXH1, E9PAW3
Search EB-eye ENSG00000105327
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MTAB-24, E-MTAB-25, ... (19 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-2450, E-MTAB-62, ... (25 experiments)

Factor Value U/D Experiments
SNU1
2
E-GEOD-15460, E-MTAB-37
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
HL-60
2
E-GEOD-24147, E-GEOD-5258
FaDu
1
E-MTAB-37
H2887
1
E-MTAB-62
SK-N-SH
1
E-MTAB-62
119 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-20677, E-GEOD-13987, E-GEOD-11755, E-GEOD-21750, ... (31 experiments)

Factor Value U/D Experiments
human foreskin fibroblast
2
E-GEOD-18265, E-GEOD-18147
monocyte
2
E-GEOD-22373, E-GEOD-11755
stromal cell
1
2
E-GEOD-10797, E-GEOD-1460, E-GEOD-3998
human embryonic stem cell
1
E-GEOD-20033
iPS cells from episomal vectors (Defined Factor)
1
E-GEOD-20033
nucleus pulposus
1
E-MEXP-2488
47 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-15960, E-GEOD-1869, E-GEOD-16363, ... (33 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
glioblastoma
1
2
E-GEOD-6014, E-GEOD-4290, E-MTAB-62
liver carcinoma
1
E-MTAB-37
carcinoma in situ, bladder tumor
1
E-MTAB-62
chronic myelogenous leukemia K562
1
E-AFMX-5
112 more value(s).


Compound treatment

studied in E-GEOD-571, E-GEOD-15205, E-TABM-782, E-GEOD-3720, E-TABM-868, ... (16 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-TABM-868, E-GEOD-3720
none
2
3
E-GEOD-2803, E-TABM-868, E-GEOD-4600, E-TABM-782, E-GEOD-995 ... (5 experiments)
phoshate buffered saline
1
E-GEOD-3720
control for EGF
1
E-GEOD-6462
Cxcl12
1
E-GEOD-7307
unknown
1
E-GEOD-7307
18 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-TABM-325, E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-21374, E-GEOD-1563, E-GEOD-755, ... (9 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-MEXP-2359, E-GEOD-4667, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-TABM-147

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-4025, E-MEXP-1482, E-GEOD-17385, E-GEOD-20847, ... (6 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-3494, E-GEOD-17476, E-GEOD-21750, E-MEXP-421, ... (11 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-6432, E-MEXP-2657, E-MEXP-1446, ... (8 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-666, E-GEOD-19519, E-GEOD-6919, ... (21 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12254, E-MEXP-561

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-21750, E-GEOD-1460, E-GEOD-4600

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

RNAi
studied in E-MEXP-2115, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22152, E-GEOD-16837, E-GEOD-19246, E-GEOD-13818

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4271, E-TABM-43

Processing time: 0.261 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM